Prevalence of industry ties in the US cancer ecosystem: a systematic review and meta-analysis

Clicks: 5
ID: 320891
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #26 of 331 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 331 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Understanding the prevalence of financial conflicts of interest is important in United States oncology, where cancer burden and annual expenditures are high. We estimated the financial conflicts of interest prevalence across the US cancer ecosystem: (1) clinical trials, (2) US Food and Drug Administration meeting participants, (3) academic medical leaders, (4) patient advocacy organizations, (5) authors of clinical practice guidelines and pathways, and (6) practicing oncologists. Methods We searched Ovid MEDLINE, Ovid Embase, Scopus, Web of Science, and the Healthcare Administration Database for oncology primary research studies and systematic reviews published since 2015 reporting a percentage of industry-related financial conflicts of interest. Two reviewers (C.K., L.W.) extracted data from eligible studies using an explicit extraction form and reached consensus. We report narrative summaries of each domain and conduct random effects meta-analysis of financial conflicts of interest prevalence on domains with at least 5 eligible studies. Results Among 36 eligible articles, 30 reported more than 50% prevalence of financial conflicts of interest in the sample. Financial conflicts of interest prevalence ranges varied within domains: 36.8%-89.0% of cancer clinical trials, 65%-92.1% of US Food and Drug Administration meeting speakers, 76%-100% among academic medical leaders, 56%-98.1% of patient advocacy organizations, 46.4%-98.4% of clinical practice guideline and pathway authors, and 24.7%-100% of clinical oncologists. Two domains (cancer trials and practicing oncologists) were eligible for meta-analysis. The pooled prevalence of industry sponsorship in clinical trials was 69% (95% CI = 62% to 77%), and the pooled prevalence of industry general payments to practicing oncologists was 61% (95% CI = 47% to 75%). Conclusion Financial conflicts of interest prevalence exceeds 50% across multiple levels of the cancer ecosystem, warranting close monitoring to limit impact on clinical decision-making and patient outcomes.
Reference Key
openalex_W7168266727 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Colin J Kim, Lily M Waddell, Zsuzsanna Nemeth, Cary P Gross
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag175
URL
https://doi.org/10.1093/jnci/djag175
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.